Literature DB >> 12112069

Blockade of blocking antibodies in Guillain-Barré syndromes: "unblocking" the mystery of action of intravenous immunoglobulin.

Marinos C Dalakas.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 12112069     DOI: 10.1002/ana.10259

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  5 in total

1.  Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey.

Authors: 
Journal:  J Neurol       Date:  2003-05       Impact factor: 4.849

Review 2.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

Review 3.  Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury.

Authors:  Vivien Thom; Thiruma V Arumugam; Tim Magnus; Mathias Gelderblom
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

Review 4.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

5.  Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice.

Authors:  Maria M Dimitriadou; Haris Alexopoulos; Sofia Akrivou; Eleni Gola; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.